This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Persons with schizophrenia are known to be at high risk for obesity and the development of diabetes and have significantly higher body mass indexes and larger percentages of introabdominal fat than do persons without schizophrenia. When treated with the most frequently used and preferred pharmacological agents, the group of drugs referred to as the atypical antipsychotic drugs, weight gain for those with schizophrenia is often rapid and excessive. The mechanism underlying this response is not yet clearly understood but early evidence suggests that insulin resistance may play a major role.
The specific aim of this exploratory pilot study is to examine insulin resistance, body fat percentage and distribution among non-obese, schizophrenic, African-American women taking a single atypical antipsychotic drug (risperidone).
Showing the most recent 10 out of 693 publications
